The 2-Deoxy-D-glucose (2DG) drug which has received the Drugs Controller General of India (DCGI) nod for emergency use as adjunct therapy for hospitalized moderate to severe #Covid19 patients was tested for the first time on cancer patients in Madhya Pradesh by Defence Research and Development Organisation (DRDO) Gwalior. Intensive investigations were carried out by the scientists, say officials.
“We started working on this drug for curing cancer in 1998. Since the results were very #cheering, investigations went on and we got it patented in 2002-2004,” says Paritosh Malviya, the public relation officer (PRO) at DRDO, Gwalior.
Ministry of #defense (MoD) mentioned it in its annual report 2003-04 saying “Clinical trials using 2-deoxy-DGlucose (2-DG) to improve the efficacy of #radiotherapy of cancer in patients with malignant brain tumor has yielded very encouraging results with enhanced survival and improved quality of life. Scientists have also produced an indigenous 2-DG which is being tested”.